Larimar Therapeutics Inc Asset Resilience Ratio
Larimar Therapeutics Inc asset resilience ratio. Larimar Therapeutics Inc (LRMR) has an Asset Resilience Ratio of 38.46% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Larimar Therapeutics Inc defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Larimar Therapeutics Inc (2014–2025)
Asset resilience ratio of Larimar Therapeutics Inc from 2014 to 2025. This chart shows how Larimar Therapeutics Inc's Asset Resilience Ratio has changed over time. Read Larimar Therapeutics Inc debt and liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Larimar Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see LRMR total asset value.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $63.58 Million | 38.46% |
| Total Liquid Assets | $63.58 Million | 38.46% |
Asset Resilience Insights
- Very High Liquidity: Larimar Therapeutics Inc maintains exceptional liquid asset reserves at 38.46% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Larimar Therapeutics Inc Industry Peers by Asset Resilience Ratio
Compare Larimar Therapeutics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578 |
Biotechnology | 21.11% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Chengdu Easton Biopharmaceuticals Co Ltd
SHG:688513 |
Biotechnology | 35.16% |
|
China Resources Boya Bio pharmaceutical Group Co Ltd
SHE:300294 |
Biotechnology | 23.15% |
|
Wuhan Keqian Biology Co Ltd
SHG:688526 |
Biotechnology | 19.42% |
|
Achieve Life Sciences Inc
F:SP4P |
Biotechnology | 3.60% |
Larimar Therapeutics Inc Asset Resilience Ratio by Year (2014–2025)
Larimar Therapeutics Inc asset resilience ratio by year from 2014 to 2025. The table below shows the annual Asset Resilience Ratio data for Larimar Therapeutics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 35.27% | $51.44 Million | $145.84 Million | -39.76pp |
| 2024-12-31 | 75.03% | $150.24 Million | $200.22 Million | +12.45pp |
| 2023-12-31 | 62.59% | $60.04 Million | $95.94 Million | -9.88pp |
| 2022-12-31 | 72.47% | $91.60 Million | $126.41 Million | -- |
| 2021-12-31 | 0.00% | $0.00 | $78.67 Million | -- |
| 2020-12-31 | 23.39% | $24.49 Million | $104.69 Million | -33.06pp |
| 2018-12-31 | 56.45% | $68.73 Million | $121.76 Million | -1.62pp |
| 2017-12-31 | 58.08% | $61.27 Million | $105.51 Million | -15.50pp |
| 2016-12-31 | 73.58% | $96.84 Million | $131.62 Million | -5.47pp |
| 2015-12-31 | 79.05% | $149.48 Million | $189.11 Million | +30.24pp |
| 2014-12-31 | 48.81% | $57.36 Million | $117.52 Million | -- |
About Larimar Therapeutics Inc
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal disease. The company is based in Bala Cynwyd, Pennsylvania.